Mettrum Health (TSXV:MT) released its fourth quarter and full-year 2016 financial results on Wednesday.
According to the press release:
Q4 2016 versus Q3 Financial Highlights:
  • Revenues increased 35% to $2,714,468
  • Grams sold increased 32% to 305,950 grams
  • Gross Margin increased 47% to $1,993,109
  • Adjusted EBITDA loss improved by 38% to a loss of $823,066
  • Registered clients increased by 44% to 7,200 (as at June 29, 2016 – 12,000, a 67% increase since March 31, 2016)

Mettrum Health Corp. (“Mettrum” or the “Company“) (TSX VENTURE:MT), a fully integrated provider of cannabis products, announced today its fourth quarter and full fiscal year 2016 financial results for the period ended March 31, 2016.

Figures in
For the three months
ended Mar 31, 2016
For the three months
ended Dec 31, 2015
For the three months
ended Mar 31, 2015
For the year ended Mar 31, 2016 For the year ended Mar 31, 2015
Grams and Gram equivalents sold 305,950 230,995 115,065 909,235 418,372
Revenue 2,714,468 2,016,863 847,690 7,691,574 3,058,711
Gross profit 1,993,109 1,351,286 571,850 5,001,756 1,297,567
Operating expenses 3,372,309 3,244,850 2,421,909 12,313,959 7,508,814
Adjusted EBITDA (823,066 ) (1,337,989 ) (1,424,683 ) (5,395,037 ) (5,374,657 )
Loss from operations (1,379,200 ) (1,893,564 ) (1,850,059 ) (7,312,203 ) (6,211,247 )
Net loss (1,421,201 ) (1,882,451 ) (1,795,416 ) (7,298,962 ) (7,035,936 )
Net loss per share basic and diluted (0.04 ) (0.06 ) (0.05 ) (0.22 ) (0.27 )

Operating Highlights

  • Mettrum is currently licensed to produce and sell dried cannabis and cannabis extracts from each of its three facilities which, on a combined basis, are approximately 90,000 square feet.
  • Mettrum is currently licensed to produce 3,550 kgs of dried cannabis annually and has current available production capacity of up to 6,000 kgs annually.
  • On a fully built out basis, which is expected by the end of the year, Mettrum’s, total production capacity will increase to up to 12,000 kgs annually
  • Mettrum Originals entered into a three-year partnership with Live Nation to name Toronto’s Molson Canadian Amphitheatre’s grass seating area “The Mettrum Originals Lawn”, and including the right to sample and sell Mettrum Originals’ products at the venue.
  • Mettrum Originals products are now sold at over 2,000 retailers in Canada and the United States.
  • Mettrum has entered into a supply and services agreement with Agriculture Victoria (Department of Economic Development, Jobs, Transport and Resources), on behalf of the Victorian Government in Australia. Mettrum has received an export permit from Health Canada to export starter material and has subsequently shipped that material and will provide advisory and consulting services to Agriculture Victoria. This arrangement is for the cannabis horticultural research trial being undertaken by Agriculture Victoria.

Fourth Quarter ended March 31, 2016 Review

  • Revenues increased 35% to $2,714,468 versus $2,016,863 during the third quarter ended December 31, 2015.
  • Average selling price per gram increased to $8.23 during the fourth quarter ended March 31, 2016 from $7.90 during the third quarter ended December 31, 2015.
  • Gross margin increased by 47% to $1,993,109 or 73% of sales, from $1,351,286 or 67% of sales during the third fourth quarter.
  • Growing costs were reduced by 2% to $2.49 per gram for the quarter ended March 31, 2016 from $2.55 for the third quarter ended December 31, 2015.
  • Adjusted EBITDA loss significantly improved by 38% to a loss of $823,066 for the quarter ended March 31, 2016 versus a loss of $1,337,989 for the third quarter ended December 31, 2015.
  • As at March 31, 2016, Mettrum’s registered client count increased to 7,200, representing a 44% increase over December 31, 2015. As at the date of this report, Mettrum is serving the needs of approximately 12,000 registered clients, representing a 67% increase in customer registration from March 31, 2016 to date.

To view the Quarterly Sales graph, please click on the following link:
To view the Quarterly Clients graph, please click on the following link:
Fiscal Year ended March 31, 2016 Review

  • Revenues increased 151% to $7,691,574 versus $3,058,711 during the previous year.
  • Average selling price per gram increased to $7.87 from $7.31 during fiscal 2016.
  • Gross margin increased by 285% to $5,001,756 or 65% or sales, from $1,297,567 or 42 % of sales during fiscal 2016.
  • Adjusted EBITDA loss amounted to a loss of $5,395,037 for the full year ended March 31, 2016 versus a loss of $5,374,657 in fiscal 2015.

As at March 31, 2016, the Company maintained a solid balance sheet with a net cash position of approximately $7.1 million. Subsequently, Mettrum completed a financing on May 10, 2016 for $7.8 million of net proceeds.
“I am very pleased with our performance over the past year. The final quarter capped off a year of continuously improving growth in revenue and operating margins. We’re looking forward to further success during the coming year,” noted Michael Haines, CEO of Mettrum. “Fiscal 2017 is off to a strong start. With all three of our facilities licensed for production and sale of dried cannabis and cannabis extracts, we will continue to grow the business and achieve cash flow break even while maintaining market share. Mettrum will continue to build upon our physician centric medical business and due to our current and future production capacity, and operational expertise, the company is exceptionally well positioned to be a major player when the recreational market opens up in Canada. It is our goal to launch our first retail oriented products within the year.”
About Mettrum Health Corp.
Mettrum Health Corp. is a Tier 1 Industry Issuer listed on TSX Venture Exchange. Mettrum Ltd., a wholly owned subsidiary of the Company, is a Toronto-based company and a licensed producer of medical cannabis under the MMPR, which came into effect on October 1, 2013. Mettrum received its first license from Health Canada under the MMPR on November 1, 2013 and began production of medical cannabis at its first production facility in Bowmanville, Ontario. Mettrum received its second license from Health Canada under the MMPR on December 11, 2014 for its Mettrum Creemore facility in Clearview, Ontario. Mettrum received its third license from Health Canada under the MMPR on December 17, 2015 for its new 60,000 square foot production and distribution facility in Bowmanville, Ontario. With the Company’s three licenses, Mettrum is a leading producer and vendor of medical cannabis under the MMPR system. In addition, through its wholly owned subsidiary Mettrum Hempworks, Mettrum also is a licensed producer and distribution of industrial cannabis (hemp) products, including Mettrum’s functional food line, Mettrum Originals, under the Industrial Hemp Regulations (Canada) issued pursuant to the Controlled Drugs and Substances Act (Canada). For more information, visit: and
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the results of operations. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company and Mettrum disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this Press release.

CANBUD Distribution Corp. (CSE:CBDX, FSE:CD0) leverages on timely and methodical execution of its revenue generating plan. It operates a trinitarian enterprise model in the plant-based protein, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) spaces. (

Keep reading... Show less


Keep reading... Show less

Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products

Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.

Keep reading... Show less

Further to its press release dated April 12, 2021, Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that it has oversubscribed and upsized its non-brokered private placement (the “Offering”) due to strong investor demand. The Company now anticipates that the Offering will be completed for gross proceeds of not less than $550,000.00, consisting of not less than 2,910,053 units (“Units”) at a price of $0.189 per Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one Common Share purchase warrant (a “Warrant”). Each Warrant is exercisable to acquire one Common Share at an exercise price of C$0.38 per Common Share for a period of 36 months from the date of closing of the Offering (the “Closing Date”), scheduled for April 22, 2021. The Units will have a hold period of four months and one day from the date of issuance.

Ayurcann CEO Igal Sudman commented: “We are very pleased with the demand we are seeing for the Offering. The feedback we have received to date is showing that our business is resonating with investors. We’re looking forward to closing the offering and proceeding with the planned Phase 2 build out, which will help greatly increase our facility’s capacity.”

Keep reading... Show less

UK InstaCoin APP Promises to Open NFTs up to the Masses through Social Media

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on its recent investment in InstaCoin Technologies Ltd., a newly formed UK entity

Keep reading... Show less